Eli Lilly and Company - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 250 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Eli Lilly and Company - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Eli Lilly and Company - Product Pipeline Review - 2014', provides an overview of the Eli Lilly and Company's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Eli Lilly and Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Eli Lilly and Company including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Eli Lilly and Company's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Eli Lilly and Company's pipeline products

Reasons to buy

- Evaluate Eli Lilly and Company's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Eli Lilly and Company in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Eli Lilly and Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Eli Lilly and Company and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eli Lilly and Company
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Eli Lilly and Company and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Eli Lilly and Company Snapshot 7
Eli Lilly and Company Overview 7
Key Information 7
Key Facts 7
Eli Lilly and Company - Research and Development Overview 8
Key Therapeutic Areas 8
Eli Lilly and Company - Pipeline Review 17
Pipeline Products by Stage of Development 17
Pipeline Products - Monotherapy 18
Pipeline Products - Partnered Products 19
Pipeline Products - Out-Licensed Products 22
Eli Lilly and Company - Pipeline Products Glance 25
Eli Lilly and Company - Late Stage Pipeline Products 25
Eli Lilly and Company - Clinical Stage Pipeline Products 29
Eli Lilly and Company - Early Stage Pipeline Products 36
Eli Lilly and Company - Drug Profiles 39
cetuximab 39
dulaglutide 46
insulin glargine 49
ramucirumab 51
tadalafil 56
vancomycin 58
baricitinib 59
duloxetine hydrochloride DR 61
evacetrapib 63
insulin peglispro 65
ixekizumab 67
LY-2835219 68
necitumumab 69
solanezumab 71
tabalumab 73
teriparatide 75
edivoxetine 77
galunisertib 79
blosozumab 81
emibetuzumab 82
erteberel 83
gandotinib 84
icrucumab 86
LY-2090314 87
LY-2409021 88
LY-2495655 89
LY-2510924 90
LY-2606368 91
LY-2801653 92
LY-2928057 93
LY-2940094 94
LY-2944876 95
LY-2951742 96
LY-3015014 97
LY-3016859 98
olaratumab 99
pemetrexed disodium 101
ralimetinib mesylate 107
taladegib 108
LY-3053102 109
Biologic 3 For Diabetes 110
Biologic 4 For Diabetes 111
Biologic for Crohn's Disease 112
Biologic For Lupus 113
Biologic-5 for Diabetes 114
IMC-3C5 115
IMC-CS4 116
LY-2780301 117
LY-2787106 118
LY-2874455 119
LY-2922083 120
LY-2922470 121
LY-2969822 122
LY-2979165 123
LY-3002813 124
LY-3006072 125
LY-3009120 126
LY-3022859 128
LY-3023414 129
LY-3025876 131
LY-3039478 132
LY-3045697 133
LY-3050258 134
LY-3074828 135
LY-3084077 136
LY-3090106 137
LY-3108743 138
LY-3127760 139
LY-404039 140
Small Molecule 1 for Diabetes 142
Small Molecule For Chronic Kidney Disease 143
Small Molecule for Hypertension 144
Small Molecule for Muscle Atrophy 145
Small Molecule to Agonize mGlu2/3 for Chronic Pain 146
Small Molecule to Antagonize EP4 Receptor for Osteoarthritis Pain 147
TT-401 148
cercosporamide 149
CPZEN-45 151
LLY-2707 152
LSN-2463359 153
LSN-2535717 154
LSN-2814617 155
LY-2109761 156
LY-2607540 157
LY-2857785 158
LY-364937 159
LYTAK-1 160
Monoclonal Antibody For Oncology 161
ND-09759 162
Peptide For Type 2 Diabetes And Obesity 163
Small Molecule to Inhibit mGlu5 for Pain 164
Bispecific Monoclonal Antibodies For Oncology 165
Polycyclic Guanidine Derivative for Type 2 Diabetes 166
Small Molecules to Inhibit Beta Secretase for Alzheimer's Disease 167
Eli Lilly and Company - Pipeline Analysis 168
Eli Lilly and Company - Pipeline Products by Target 168
Eli Lilly and Company - Pipeline Products by Route of Administration 173
Eli Lilly and Company - Pipeline Products by Molecule Type 174
Eli Lilly and Company - Pipeline Products by Mechanism of Action 176
Eli Lilly and Company - Recent Pipeline Updates 181
Eli Lilly and Company - Dormant Projects 208
Eli Lilly and Company - Discontinued Pipeline Products 217
Discontinued Pipeline Product Profiles 219
Eli Lilly and Company - Company Statement 229
Eli Lilly and Company - Locations And Subsidiaries 233
Head Office 233
Other Locations & Subsidiaries 233
Eli Lilly and Company - Key Manufacturing Facilities 240
Appendix 241
Methodology 241
Coverage 241
Secondary Research 241
Primary Research 241
Expert Panel Validation 241
Contact Us 242
Disclaimer 242

List of Tables
Eli Lilly and Company, Key Information 15
Eli Lilly and Company, Key Facts 15
Eli Lilly and Company - Pipeline by Indication, 2014 17
Eli Lilly and Company - Pipeline by Stage of Development, 2014 25
Eli Lilly and Company - Monotherapy Products in Pipeline, 2014 26
Eli Lilly and Company - Partnered Products in Pipeline, 2014 27
Eli Lilly and Company - Partnered Products/ Combination Treatment Modalities, 2014 28
Eli Lilly and Company - Out-Licensed Products in Pipeline, 2014 30
Eli Lilly and Company - Out-Licensed Products/ Combination Treatment Modalities, 2014 31
Eli Lilly and Company - Pre-Registration, 2014 33
Eli Lilly and Company - Filing rejected/Withdrawn, 2014 34
Eli Lilly and Company - Phase III, 2014 35
Eli Lilly and Company - Phase II, 2014 37
Eli Lilly and Company - Phase I, 2014 40
Eli Lilly and Company - Preclinical, 2014 44
Eli Lilly and Company - Discovery, 2014 46
Eli Lilly and Company - Pipeline by Target, 2014 177
Eli Lilly and Company - Pipeline by Route of Administration, 2014 181
Eli Lilly and Company - Pipeline by Molecule Type, 2014 183
Eli Lilly and Company - Pipeline Products by Mechanism of Action, 2014 184
Eli Lilly and Company - Recent Pipeline Updates, 2014 189
Eli Lilly and Company - Dormant Developmental Projects,2014 216
Eli Lilly and Company - Discontinued Pipeline Products, 2014 225
Eli Lilly and Company, Subsidiaries 241
Eli Lilly and Company, Key Manufacturing Facilities 248